why choose us

First received: July 25, 2022

Clinical Trial: TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Single-center, Prospective, Single-arm Phase II Clinical Study on the Efficacy and Safety of TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

Brief Summary: This study was designed to evaluate the effectiveness and safety of TACE?transcatheter arterial chemoembolization? combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.The primary outcome measure is to evaluate the objective response rate (ORR) of the therapy for Hepatocellular Carcinoma.The secondary Outcome measures include the duration of response (DOR), disease control rate (DCR), progression-free survival rate (PFSR) [ Time Frame: 6- and 12-month], overall survival rate (OSR) [ Time Frame: 6-…

Read more